Related Experiment Video

Updated: Nov 3, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches

Punit Saraon1, Shivanthy Pathmanathan2,3, Jamie Snider2

  • 1Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.

Oncogene
|June 3, 2021
PubMed

Insights

Receptor tyrosine kinases (RTKs) drive cancer but treatments face resistance. New technologies aim to discover novel RTK inhibitors targeting both receptors and signaling pathways to overcome treatment challenges.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial in cancer development and are key targets for cancer therapeutics.
  • Despite the success of tyrosine kinase inhibitors (TKIs), acquired resistance and tumor relapse remain significant clinical challenges.

Purpose of the Study:

  • To review the role of RTKs in cancer and the development of TKIs.
  • To highlight the challenge of acquired resistance to current RTK-targeted therapies.
  • To discuss emerging technologies for identifying novel RTK inhibitors.

Main Methods:

  • Review of existing literature on RTKs, TKIs, and cancer resistance mechanisms.
  • Analysis of recent technological advancements in drug discovery for RTK-targeted therapeutics.

Main Results:

  • RTKs are implicated in various cancers, leading to the development of numerous TKIs.
  • Acquired resistance to TKIs is a common cause of treatment failure and tumor relapse.
  • New technologies are emerging for the discovery of diverse RTK inhibitors.

Conclusions:

  • Targeting RTKs remains a critical strategy in cancer therapy.
  • Overcoming acquired resistance requires the development of novel therapeutic approaches.
  • Advancements in technology are paving the way for next-generation RTK inhibitors targeting RTKs and their signaling pathways.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K